Thomas Buchholz
Directeur/Membre du Conseil chez Nucleix Ltd.
Postes actifs de Thomas Buchholz
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Nucleix Ltd.
 Nucleix Ltd. Medical/Nursing ServicesHealth Services Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel. | Directeur/Membre du Conseil | 11/05/2020 | - |
Historique de carrière de Thomas Buchholz
Formation de Thomas Buchholz
| Tufts University School of Medicine | Doctorate Degree |
| Bucknell University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 3 |
| Israël | 2 |
Opérationnelle
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
| Director/Board Member | 1 |
Sectorielle
| Consumer Services | 3 |
| Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Nucleix Ltd.
Nucleix Ltd. Medical/Nursing ServicesHealth Services Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel. | Health Services |
- Bourse
- Insiders
- Thomas Buchholz
- Expérience
